Tigecycline Products Market

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
TIGECYCLINE PRODUCTS MARKET ANALYSIS

• Tigecycline Products Market, by Application
  (Urinary Tract Infections, Skin and Soft Tissue
  Infections, Complicated Intra-Abdominal
  Infections, Community-Acquired Bacterial
  Pneumonia, Gonorrhea, and Chlamydia), by
  Distribution Channel (Online Retail Pharmacies
  And Offline Retail Pharmacies), and by Region
  (North America, Latin America, Europe, Middle
  East, Asia Pacific, and Africa) - Size, Share,
  Outlook, and Opportunity Analysis, 2020 - 2027

3

• Market Drivers
• The increasing prevalence of gonorrhea in the
  U.S. is driving demand for tigecycline products
  in the market. For instance, according to the
  Centers for Disease Control and Preventions 2017
  report, in the U.S, around 555,608 cases of
  gonorrhea were reported. Therefore,
  pharmaceutical companies are focusing on
  launching products for treatment of bacterial
  infections due to increasing prevalence. For
  instance, in 2017, Sandoz Inc. launched AP-rated
  generic version of Tygacil (Tigecycline)
  injection at a cheaper price compared to branded
  products in order to increase affordability of
  the drug. These factors are expected to drive
  growth of global tigecycline products market.

4
COVID-19 Impact AnalysisThe
COVID-19 pandemic has affected several markets
across the globe. Pharmaceutical companies are
facing difficulties such as regulatory revisions,
changes in demand, delay in generic medicine
approvals, disruption in supply chain, and
product exportation restriction due to lockdown
policies implemented by governments. These
factors are negatively affecting the growth of
the global tigecycline products market.
5

• Market Restraints
• Tigecycline antibiotic is characterized by side
  effects such as lower back or side pain, painful
  or difficult urination, problems with vision or
  hearing, cough or hoarseness, fever or chills,
  and headache.
• Moreover,the use of  tigecycline is restricted
  due to increase in mortality in hospital-acquired
  or ventilator-associated pneumonia. Moreover,
  patients prefer oral tablets (amoxicillin) to
  injection (tigecycline) for treatment of
  bacterial infection, due to the cost
  effectiveness of oral amoxicillin. Cost of 500 mg
  amoxicillin oral tablet is US 23.99, while cost
  of the tigecycline injection is US 79.22. These
  factors are expected to restrain growth of the
  global tigecycline products market.

6
Regional Analysis

• On the basis of region, the global tigecycline
  products market is segmented into North America,
  Latin America, Europe, Asia Pacific, Middle East,
  and Africa. In North America, the demand for use
  of tigecycline is increasing due to high
  prevalence of chlamydia trachomtis.
• For instance, according to the Centers for
  Disease Control and Prevention, in 2016,
  1,598,354 cases of chlamydia trachomatis
  infection were reported in the U.S., and 497.3
  cases per 100,000 were reported in 2015.

7

• Market Trends
• Therefore, pharmaceutical companies are focusing
  on launching product for treatment of bacterial
  infectious diseases. For instance, in February
  2020, European Medicines Agency approved
  marketing authorization of tigecycline injection
  by Accord Healthcare for treatment of bacterial
  skin diseases. These factors are expected to
  drive growth of the global tigecycline products
  market during the forecast period.
•   Therefore, pharmaceutical companies are
  focusing on product launches for the treatment of
  bacterial infectious disease. For instance, in
  2016, Fresenius Kabi announced the launch of
  Tigecycline injection, a generic version of
  Pfizers tygacil with single dose vial in the
  U.S.

8

• Competitive Section
• Key players operating in the global tigecycline
  products market are Amneal Pharmaceuticals, Inc.,
  Novartis International AG, Xellia pharmaceuticals
  ApS, Accord Healthcare Inc., Apotex, Inc.,
  Aurobindo Pharma Limited, Fresenius Kabi USA LLC,
  Pfizer Inc., Abbott Laboratories, and AstraZeneca
  plc.
• Market Taxonomy
• On the basis of application, the
  global tigecycline products market is segmented
  into
• Urinary Tract Infections (UTI)
• Skin and Soft Tissue Infections
• Complicated Intra-Abdominal Infections
• Community-acquired Bacterial Pneumonia
• Gonorrhea
• Chlamydia
• Others

9

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Reference https//www.coherentmarketinsights.com/o
  ngoing-insight/tigecycline-products-market-4168

10
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

11
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

12

• Thank You!
• Kindly follow CMI Social Media Profiles for
  the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/